B
CAI

Braidwell’s Caris Life Sciences CAI Stock Holding History

Braidwell’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$147M Buy
8,256,032
+246,585
+3% +$4.41M 5.44% 1
2026
Q1 		$143M Buy
8,009,447
+193,305
+2% +$4.23M 4.78% 1
2025
Q4 		$211M Buy
7,816,142
+500,000
+7% +$14.1M 6.74% 1
2025
Q3 		$221M Hold
7,316,142
– – 6.57% 2
2025
Q2 		$195M Buy
+7,316,142
New +$197M 6.69% 2

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Braidwell's CAI Position: Q2 2026 in Review

Braidwell increased its Caris Life Sciences (CAI) stake by 3.1% in Q2 2026, buying an estimated $4.41M and bringing the position to 8,256,032 shares worth $147M. The position accounts for 5.44% of the portfolio, ranked #1.

Braidwell first reported a position in CAI in Q2 2025 and has held it in 5 quarters since. The position peaked at $221M in Q3 2025. 246 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • Braidwell held 8,256,032 shares of Caris Life Sciences worth $147M as of Q2 2026.
  • Braidwell bought 246,585 Caris Life Sciences shares in Q2 2026, an estimated $4.41M.
  • Caris Life Sciences made up 5.44% of Braidwell's portfolio in Q2 2026, its #1 holding.
  • Braidwell first reported a position in Caris Life Sciences in Q2 2025 and has held it in 5 quarters since.
  • Braidwell's Caris Life Sciences position peaked at $221M in Q3 2025.
  • 246 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Braidwell's 13F filing for Q2 2026, filed 14 Aug 2026.